TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20388042

Group type: EXPERIMENTAL
Intervention: eMOD web-based comprehensive information system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (conventional education)
Number of subjects: 40
Study: 18373577

Group type: EXPERIMENTAL
Intervention: Tailored daily messages via cellphone prompting to enhance diabetic self-care behaviour
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard diabetes self-management
Number of subjects: 30
Study: 16078923

Group type: EXPERIMENTAL
Intervention: Apheresis platelets treated with riboflavin (500 micromol per L) and UV light (6.2 J per mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control apheresis platelets (untreated)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Apheresis platelets treated with riboflavin and UV light
Number of subjects: 24
Study: 12614536

Group type: EXPERIMENTAL
Intervention: Iscador Qu (IQ)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Iscador Pini (IP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10915328

Group type: EXPERIMENTAL
Intervention: Hierarchical grading systems (e.g., grades I, II, and III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive typologic system
Number of subjects: 0
Study: 8882824

Group type: EXPERIMENTAL
Intervention: Early recoronary angiography after 6 weeks with differentiated reintervention
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Second reintervention after 1/4 year
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Type-I dissection
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Type-II dissection
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Type-IV dissection
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Type-III dissection
Number of subjects: 324
Study: 1857138

Group type: EXPERIMENTAL
Intervention: Firm system intervention with private physician groups randomized to four geographic medical wards (oncology, cardiology, nephrology, diabetes)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Problems related to the firm system intervention
Number of subjects: 350
Study: 6956376

Group type: EXPERIMENTAL
Intervention: Intrathecal (i.t.) chemoprophylaxis
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Intrathecal (i.t.) chemoprophylaxis during consolidation
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CNS chemoprophylaxis during consolidation
Number of subjects: 408

Group type: COMPARATOR
Intervention: Cranial radiotherapy plus i.t. MTX
Number of subjects: 408
Study: 31072714

Group type: EXPERIMENTAL
Intervention: Fixed loop group (EndoButton)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Adjustable loop group (TightRope)
Number of subjects: 79
Study: 28453896

Group type: EXPERIMENTAL
Intervention: Radical cystectomy (RC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Selective bladder preservation (SBP)
Number of subjects: 45
Study: 26964157

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 66

Group type: COMPARATOR
Intervention: Western medication (cetirizine hydrochloride)
Number of subjects: 66
Study: 23321375

Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tonic stimulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21300334

Group type: EXPERIMENTAL
Intervention: GnRH antagonist administered from day 2 of the menstrual cycle for 3 consecutive days, followed by standard treatment with daily injections of recombinant FSH (rFSH) starting on day 2 of the cycle at a dose of 150-225 IU/day, and GnRH antagonists from cycle day 7 onward.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard treatment with daily injections of recombinant FSH (rFSH) starting on day 2 of the cycle at a dose of 150-225 IU/day, and GnRH antagonists from cycle day 7 onward.
Number of subjects: 69
Study: 19447196

Group type: EXPERIMENTAL
Intervention: 5Fr stent
Number of subjects: 249

Group type: COMPARATOR
Intervention: 3Fr stent
Number of subjects: 249
Study: 16549466

Group type: EXPERIMENTAL
Intervention: Free plant sterols
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plant sterols esterified to fatty acids from sunflower oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plant sterols esterified to very long‐chained fatty acids from fish oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plant sterols combined with very long‐chained fatty acids from fish oil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Margarine (control)
Number of subjects: 30
Study: 15457755

Group type: EXPERIMENTAL
Intervention: Dobosiewicz method
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 10191173

Group type: EXPERIMENTAL
Intervention: 4.0-T scanner
Number of subjects: 6

Group type: COMPARATOR
Intervention: 1.5-T scanner
Number of subjects: 6
Study: 7804974

Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO), total protein equals 2 mg/ml, administered once a week for 13 weeks and then once every 2 weeks for an additional 39 weeks
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo of live vaccinia vaccine virus (V), 10(5.4) TCID50/ml, administered once a week for 13 weeks and then once every 2 weeks for an additional 39 weeks
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo of live vaccinia vaccine virus (V)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) in male patients (n = 63)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) in male patients aged 44-57 with 1-5 positive lymph nodes (n = 20)
Number of subjects: 250
Study: 2129437

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo)
Number of subjects: 13
Study: 339084

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7067069

Group type: EXPERIMENTAL
Intervention: Hyposensitization with rye grass extract
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Children highly sensitized to rye allergen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Post-grass pollen season
Number of subjects: 36
Study: 30561729

Group type: EXPERIMENTAL
Intervention: High hemoglobin group (12.5-13.5 g/dL)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Low hemoglobin group (10.5-11.5 g/dL)
Number of subjects: 127
Study: 29504369

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with high dose Dermatophagoides farinae
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26576716

Group type: EXPERIMENTAL
Intervention: Autonomic Regulation Therapy (ART) via vagus nerve stimulation (VNS)
Number of subjects: 60
Study: 23985355

Group type: EXPERIMENTAL
Intervention: Group music therapy, no restrictions on frequency, duration, or contents.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 113
Study: 23273285

Group type: EXPERIMENTAL
Intervention: Six standardized clinical tests focusing on movement control for back and hip
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combinations of one low- and one high-threshold test
Number of subjects: 33
Study: 20104222

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg per day in 6-week cycles (4 weeks on, 2 weeks off treatment)
Number of subjects: 750
Study: 17674351

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 63
Study: 16128597

Group type: EXPERIMENTAL
Intervention: Colestilan (four tablets administered in divided doses with three glasses of water before dinner and bedtime for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (three glasses of water before dinner and bedtime for 12 weeks)
Number of subjects: 40
Study: 11802259

Group type: EXPERIMENTAL
Intervention: Living with a mother in a supportive family
Number of subjects: 522
Study: 10649921

Group type: EXPERIMENTAL
Intervention: LB2 Primer applied for 30 seconds
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 34% phosphoric acid etching for 15 seconds
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated dentin smear layer
Number of subjects: 24
Study: 8590742

Group type: EXPERIMENTAL
Intervention: Primary angioplasty as a reperfusion approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rescue angioplasty after failed thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 2073487

Group type: EXPERIMENTAL
Intervention: Group 1 (fast injection, mean 0.54 ml/second)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 2 (slow injection, 0.05 ml/second)
Number of subjects: 40
Study: 6986746

Group type: EXPERIMENTAL
Intervention: External pressure circulatory assistance for 4 or more hours within the first 24 hours after admission
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: External pressure circulatory assistance for 3 or more hours
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Combined group of patients with 3 or more and 4 or more hours of treatment
Number of subjects: 258
Study: 29800114

Group type: EXPERIMENTAL
Intervention: High qSOFA score (2)
Number of subjects: 6569

Group type: EXPERIMENTAL
Intervention: Moderate qSOFA score (1)
Number of subjects: 6569

Group type: EXPERIMENTAL
Intervention: High SIRS criteria (2)
Number of subjects: 6569

Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 6569
Study: 26995688

Group type: EXPERIMENTAL
Intervention: 22G side-port needle
Number of subjects: 160

Group type: COMPARATOR
Intervention: 22G standard needle
Number of subjects: 160
Study: 24502951

Group type: EXPERIMENTAL
Intervention: Goat milk formula
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cow milk formula
Number of subjects: 200
Study: 22878073

Group type: EXPERIMENTAL
Intervention: Peer leaders conducted organ donation discussions and showed a tailored DVD for African American churches.
Number of subjects: 22
Study: 17239068

Group type: EXPERIMENTAL
Intervention: Prevention started when non-blanchable erythema appeared (experimental group, n = 826)
Number of subjects: 1617

Group type: COMPARATOR
Intervention: Standard risk assessment method (control group, n = 791)
Number of subjects: 1617
Study: 15861942

Group type: EXPERIMENTAL
Intervention: Traditional course
Number of subjects: 160

Group type: COMPARATOR
Intervention: Integrated course
Number of subjects: 160
Study: 12019281

Group type: EXPERIMENTAL
Intervention: Mild bicycle exercise (30 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control evaluation (CTRL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: POSTEX (after exercise)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: POSTEX+LBNP (after exercise and LBNP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LBNP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: POSTEX
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: POSTEX+LBNP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study: 9498653

Group type: EXPERIMENTAL
Intervention: Cholesterol supplementation of 800 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8541279

Group type: EXPERIMENTAL
Intervention: EPA‐EE (18 g/d for 7 days)
Number of subjects: 10
Study: 2172288

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 81927

Group type: EXPERIMENTAL
Intervention: Hyposensitisation with Dermatophagoides pteronyssinus tyrosine absorbate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31358408

Group type: EXPERIMENTAL
Intervention: 2-dose vaccination (2D) on days 0 and 28
Number of subjects: 107

Group type: COMPARATOR
Intervention: 3-dose vaccination (3D) on days 0, 7, and 28
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 2-dose vaccination (2D) post-booster
Number of subjects: 107

Group type: COMPARATOR
Intervention: 3-dose vaccination (3D) post-booster
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 2-dose vaccination (2D) at 7-day post-booster
Number of subjects: 107

Group type: COMPARATOR
Intervention: 3-dose vaccination (3D) at 7-day post-booster
Number of subjects: 107
Study: 27916620

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/Formoterol Metered Dose Inhaler (GFF MDI) 18/9.6 μg
Number of subjects: 3718

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Metered Dose Inhaler (GP MDI) 18 μg
Number of subjects: 3718

Group type: EXPERIMENTAL
Intervention: Formoterol Metered Dose Inhaler (FF MDI) 9.6 μg
Number of subjects: 3718

Group type: COMPARATOR
Intervention: Placebo Metered Dose Inhaler (MDI)
Number of subjects: 3718
Study: 26626341

Group type: EXPERIMENTAL
Intervention: Community-based Direct Observation of Treatment (CBDOT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hospital-based Direct Observation of Treatment (HBDOT)
Number of subjects: 150
Study: 22872005

Group type: EXPERIMENTAL
Intervention: G-CSF (10 μg/kg/day for 3 consecutive days with an additional half-dose 4 hours before surgery)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no G-CSF)
Number of subjects: 24
Study: 21455076

Group type: EXPERIMENTAL
Intervention: Infrapatellar nerve block (IPNB; 10 ml levobupivacaine 0.5%)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham block with isotonic saline
Number of subjects: 64
Study: 18095747

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 45 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16557381

Group type: EXPERIMENTAL
Intervention: Postoperative interferon alpha (5 micro i.m. tiw for 18 months)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study: 12673604

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day (prior exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day (prior exposure)
Number of subjects: 0
Study: 11912812

Group type: EXPERIMENTAL
Intervention: Monthly follow-up
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3-month follow-up
Number of subjects: 30
Study: 8866392

Group type: EXPERIMENTAL
Intervention: Superovulation plus IUI (36 patients)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Superovulation alone (32 patients)
Number of subjects: 68
Study: 1512807

Group type: EXPERIMENTAL
Intervention: Various treatment strategies for substance abuse; specific dosages and durations not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matching clients to alternative treatment strategies; specific strategies not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term treatment approaches; specific details not available.
Number of subjects: 0
Study: 6747752

Group type: COMPARATOR
Intervention: Standard dose (0.5 ml) DTP vaccine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Modified dose (0.25 ml) DTP vaccine
Number of subjects: 80
Study: 31748288

Group type: EXPERIMENTAL
Intervention: Tailored brief behavioural sleep intervention
Number of subjects: 234

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 234
Study: 30045425

Group type: EXPERIMENTAL
Intervention: Snack containing green leafy vegetables, fruit, and milk (mean 54.1 mg ALA)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control snack containing low micronutrient foods (mean 4.1 mg ALA)
Number of subjects: 222
Study: 27487142

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 265

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Lomustine plus bevacizumab
Number of subjects: 265

Group type: COMPARATOR
Intervention: Lomustine
Number of subjects: 265
Study: 26008757

Group type: EXPERIMENTAL
Intervention: Increasing a modified Sensory Motor Rhythm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increasing Upper Alpha
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham/control group (random reward)
Number of subjects: 30
Study: 24041259

Group type: EXPERIMENTAL
Intervention: Intervention from GP to parents highlighting the importance of maintaining asthma medication
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 14000
Study: 20828635

Group type: EXPERIMENTAL
Intervention: GERA (genetic and environmental risk assessment) group
Number of subjects: 562

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 562
Study: 18285374

Group type: EXPERIMENTAL
Intervention: SpO2 monitoring
Number of subjects: 19

Group type: COMPARATOR
Intervention: TcPO2 monitoring
Number of subjects: 19
Study: 16410446

Group type: EXPERIMENTAL
Intervention: ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Ld-CHOP (low-dose CHOP)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Ld-CHOP
Number of subjects: 485

Group type: COMPARATOR
Intervention: VS (vincristine and steroid)
Number of subjects: 485
Study: 14643838

Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg bid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amantadine (0 mg bid)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12, 25, and 50 mg)
Number of subjects: 10
Study: 10862807

Group type: EXPERIMENTAL
Intervention: Daily buprenorphine (16 mg/70 kg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Thrice-weekly buprenorphine (34 mg/70 kg on Fridays and Sundays, 44 mg/70 kg on Tuesdays)
Number of subjects: 92
Study: 9197932

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY (derived from egg yolks from immunized hens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control IgY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY (10% sucrose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY (without sucrose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY
Number of subjects: 0
Study: 8156957

Group type: EXPERIMENTAL
Intervention: FVS (Aerosolum Diaiepami Compositae or Flvalscop)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 120
Study: 3351689

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline plus diuretics
Number of subjects: 16
Study: 28929443

Group type: EXPERIMENTAL
Intervention: 36 hours fasting
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Midazolam and S-warfarin
Number of subjects: 9
Study: 28448779

Group type: EXPERIMENTAL
Intervention: Pharmacist-led care program (5 face-to-face educational sessions over 12 months)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Pharmacist-led care program
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study: 26209163

Group type: EXPERIMENTAL
Intervention: Anesthetic blockade of the posterior interosseous nerve (PIN)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Circumferential topical anesthetic blockade of skin surrounding the wrist
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo intervention with saline injection or inert ultrasound gel (control)
Number of subjects: 80
Study: 24938449

Group type: EXPERIMENTAL
Intervention: LBS plus doxazosin
Number of subjects: 360

Group type: COMPARATOR
Intervention: LBS placebo plus doxazosin
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: LBS plus doxazosin placebo
Number of subjects: 360
Study: 22491250

Group type: EXPERIMENTAL
Intervention: Tonsillectomy (n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (n = 14)
Number of subjects: 29
Study: 20426588

Group type: EXPERIMENTAL
Intervention: Indirect/closed sinus floor elevation method
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (intra‐individual control)
Number of subjects: 31
Study: 18547178

Group type: EXPERIMENTAL
Intervention: Single cross-linked hyaluronic acid (SCHA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Double cross-linked hyaluronic acid (DCHA)
Number of subjects: 10
Study: 16089271

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate‐electrolyte (CE6)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 8% carbohydrate‐electrolyte (CE8)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study: 12634887

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 0
Study: 10635187

Group type: EXPERIMENTAL
Intervention: CNC-milled frameworks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional cast frameworks
Number of subjects: 20
Study: 8960447

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Reversible Ischaemia
Number of subjects: 101
Study: 1311653

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both hormones (Angiotensin II and Noradrenaline)
Number of subjects: 56